(Q45740593)

15 December 2017

title

In vivo dynamics and pathogenicity of wild-type and resistant Hepatitis B virus during long-term lamivudine monotherapy - a clinical note (English)

1 reference

15 December 2017

1 reference

1 reference

Zöllner B

1

1 reference

15 December 2017

Stoehr A

2

1 reference

15 December 2017

Plettenberg A

3

1 reference

15 December 2017

Feucht H

4

1 reference

15 December 2017

Schröter M

5

1 reference

15 December 2017

Schäfer P

6

1 reference

15 December 2017

Laufs R

7

1 reference

15 December 2017

publication date

1 September 2000

1 reference

Journal of Clinical Virology

15 December 2017

published in

1 reference

15 December 2017

volume

17

1 reference

15 December 2017

issue

3

1 reference

15 December 2017

page(s)

183-188

1 reference

Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group

15 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2800%2900092-5

7 January 2021

Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2800%2900092-5

7 January 2021

Efficacy of lamivudine on replication of hepatitis B virus in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2800%2900092-5

7 January 2021

Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2800%2900092-5

7 January 2021

A preliminary trial of lamivudine for chronic hepatitis B infection

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2800%2900092-5

7 January 2021

Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC (3TC) resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2800%2900092-5

7 January 2021

Clinical impact of lamivudine resistance in chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2800%2900092-5

7 January 2021

Genotypic and phenotypic characterization of HIV-1 isolated from patients receiving (--)-2',3'-dideoxy-3'-thiacytidine

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2800%2900092-5

7 January 2021

Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2800%2900092-5

7 January 2021

Identification of more than one mutation in the hepatitis B virus polymerase gene arising during prolonged lamivudine treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2800%2900092-5

7 January 2021

Clinical implications of lamivudine resistance by HBV

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2800%2900092-5

7 January 2021

Detection of hepatitis B virus DNA in serum by a simple spot hybridization technique: comparison with results for other viral markers.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2800%2900092-5

7 January 2021

Drug-resistant genotyping in HIV-1 therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2800%2900092-5

7 January 2021

Assay of hepatitis B virus genome titers in sera of infected subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2800%2900092-5

7 January 2021

10.1016/S1386-6532(00)00092-5

Identifiers

DOI

1 reference

15 December 2017

1 reference